

PharmaFluidics raises 7.3 Million Euro financing

11 January 2018 | News

PharmaFluidics NV, a game-changing innovator in the field of analytical chromatography, raised 7.3 million euro to Expand Commercialization of Novel Micro-Chip Device for Biomarker, Diagnostics and Drug Development Application



Micro-Chip chromatography company PharmaFluidics closed a financing round of 7.3 million euro from investors including holding company FPIM-SFPI, and family offices Heran (Annie Vereecken) and RMM (Rudi Marien).

The existing investors PMV, Qbic, Theodorus, Innovation Fund and Volksvermogen reaffirm their confidence in the company and also participated in this financing round.

The VUB offshoot is a disruptive player in the field of micro-Chip Chromatography.

Their unique technology the 'µPAC™ column' series - offers unprecedented robustness and reproducibility as well as state-of-the-art sensitivity and resolution performance.

The first clients academic labs in bio-analysis, bio-pharmaceuticals and diagnostics companies - have confirmed these outstanding characteristics of the μPAC^{TM} technology.

The new funds will be used to further develop the Pillar Array technology platform, to expand the μPAC^{TM} product range, and to scale up production and global sales.

The company started shipping µPAC?? columns in September 2017 and has since served proteomics laboratories, medical centers and pharmaceutical companies on three continents: Europe, the USA and Asia.

Its pioneering product is very well received and has convinced pioneer users and key opinion leaders in proteomics to use micro-Chip based chromatography.

The company will focus on intensifying international growth, supported by initial, promising sales.